NO329133B1 - Anvendelse av en FPT-inhibitor ved fremstilling av et farmasoytisk preparat for behandling av kreft i en pasient og for regresjon av tumorvolum i en kreftpasient - Google Patents

Anvendelse av en FPT-inhibitor ved fremstilling av et farmasoytisk preparat for behandling av kreft i en pasient og for regresjon av tumorvolum i en kreftpasient Download PDF

Info

Publication number: NO329133B1
Authority: NO; Norway
Prior art keywords: inhibitor; cancer; use according; ras; fpt
Prior art date: 1999-04-09

Application number

NO20014897A

Other languages

English (en)

Norwegian (no)

Other versions

NO20014897D0 (no

NO20014897L (no

Inventor

Tattanahalli L Nagabhushan

Walter Robert Bishop

Diana L Brassard

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-09

Filing date

2001-10-08

Publication date

2010-08-30

2001-10-08 Application filed by Schering Corp filed Critical Schering Corp

2001-10-08 Publication of NO20014897D0 publication Critical patent/NO20014897D0/no

2001-12-10 Publication of NO20014897L publication Critical patent/NO20014897L/no

2010-08-30 Publication of NO329133B1 publication Critical patent/NO329133B1/no

Links

239000003112 inhibitor Substances 0.000 title claims description 147
206010028980 Neoplasm Diseases 0.000 title claims description 58
238000011282 treatment Methods 0.000 title claims description 53
201000011510 cancer Diseases 0.000 title claims description 35
238000002360 preparation method Methods 0.000 title claims description 18
239000000825 pharmaceutical preparation Substances 0.000 title claims description 12
108010014186 ras Proteins Proteins 0.000 claims description 105
102000016914 ras Proteins Human genes 0.000 claims description 104
230000037361 pathway Effects 0.000 claims description 62
230000019491 signal transduction Effects 0.000 claims description 55
238000006243 chemical reaction Methods 0.000 claims description 31
230000006907 apoptotic process Effects 0.000 claims description 27
102000009465 Growth Factor Receptors Human genes 0.000 claims description 25
108010009202 Growth Factor Receptors Proteins 0.000 claims description 25
239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 18
229940124647 MEK inhibitor Drugs 0.000 claims description 17
239000002246 antineoplastic agent Substances 0.000 claims description 15
230000004611 cancer cell death Effects 0.000 claims description 13
230000002195 synergetic effect Effects 0.000 claims description 12
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 11
102000001301 EGF receptor Human genes 0.000 claims description 8
108060006698 EGF receptor Proteins 0.000 claims description 8
101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 8
229940127089 cytotoxic agent Drugs 0.000 claims description 8
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
-1 leuprolide Chemical compound 0.000 claims description 6
201000005202 lung cancer Diseases 0.000 claims description 6
208000020816 lung neoplasm Diseases 0.000 claims description 6
208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
206010005003 Bladder cancer Diseases 0.000 claims description 5
229930012538 Paclitaxel Natural products 0.000 claims description 5
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
229960001592 paclitaxel Drugs 0.000 claims description 5
201000002528 pancreatic cancer Diseases 0.000 claims description 5
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 5
239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 5
206010006187 Breast cancer Diseases 0.000 claims description 4
208000026310 Breast neoplasm Diseases 0.000 claims description 4
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 4
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 4
208000029742 colonic neoplasm Diseases 0.000 claims description 4
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 4
229960002340 pentostatin Drugs 0.000 claims description 4
FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims description 4
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 4
150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 claims description 4
206010009944 Colon cancer Diseases 0.000 claims description 3
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
206010033128 Ovarian cancer Diseases 0.000 claims description 3
206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
108091008606 PDGF receptors Proteins 0.000 claims description 3
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims description 3
206010060862 Prostate cancer Diseases 0.000 claims description 3
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 3
229960005277 gemcitabine Drugs 0.000 claims description 3
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 3
229940043355 kinase inhibitor Drugs 0.000 claims description 3
201000001441 melanoma Diseases 0.000 claims description 3
229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims description 3
150000003384 small molecules Chemical group 0.000 claims description 3
229960004964 temozolomide Drugs 0.000 claims description 3
FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims description 2
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 2
102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 claims description 2
GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 claims description 2
DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 claims description 2
NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 2
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 2
IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 claims description 2
VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims description 2
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
108010024976 Asparaginase Proteins 0.000 claims description 2
108010006654 Bleomycin Proteins 0.000 claims description 2
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 2
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 2
JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 claims description 2
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
108010092160 Dactinomycin Proteins 0.000 claims description 2
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 2
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
208000032612 Glial tumor Diseases 0.000 claims description 2
206010018338 Glioma Diseases 0.000 claims description 2
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 2
108010069236 Goserelin Proteins 0.000 claims description 2
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 2
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 2
102000014150 Interferons Human genes 0.000 claims description 2
108010050904 Interferons Proteins 0.000 claims description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
108010000817 Leuprolide Proteins 0.000 claims description 2
HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 claims description 2
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 2
GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 claims description 2
201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 2
229960000473 altretamine Drugs 0.000 claims description 2
ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims description 2
229960003437 aminoglutethimide Drugs 0.000 claims description 2
XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims description 2
229960001220 amsacrine Drugs 0.000 claims description 2
229940034982 antineoplastic agent Drugs 0.000 claims description 2
201000001531 bladder carcinoma Diseases 0.000 claims description 2
229960001561 bleomycin Drugs 0.000 claims description 2
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
229960002092 busulfan Drugs 0.000 claims description 2
229960004562 carboplatin Drugs 0.000 claims description 2
190000008236 carboplatin Chemical compound 0.000 claims description 2
229960005243 carmustine Drugs 0.000 claims description 2
229960004630 chlorambucil Drugs 0.000 claims description 2
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 2
BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 claims description 2
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
229960004316 cisplatin Drugs 0.000 claims description 2
229960004397 cyclophosphamide Drugs 0.000 claims description 2
229960000684 cytarabine Drugs 0.000 claims description 2
229960003901 dacarbazine Drugs 0.000 claims description 2
229960000640 dactinomycin Drugs 0.000 claims description 2
229960000975 daunorubicin Drugs 0.000 claims description 2
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 claims description 2
229960000452 diethylstilbestrol Drugs 0.000 claims description 2
229960004679 doxorubicin Drugs 0.000 claims description 2
NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 claims description 2
229950004683 drostanolone propionate Drugs 0.000 claims description 2
229960001904 epirubicin Drugs 0.000 claims description 2
229960001842 estramustine Drugs 0.000 claims description 2
FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims description 2
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
229960005420 etoposide Drugs 0.000 claims description 2
229960000961 floxuridine Drugs 0.000 claims description 2
ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 2
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 2
229960005304 fludarabine phosphate Drugs 0.000 claims description 2
229960002949 fluorouracil Drugs 0.000 claims description 2
YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 claims description 2
229960001751 fluoxymesterone Drugs 0.000 claims description 2
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 2
229960002074 flutamide Drugs 0.000 claims description 2
UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims description 2
229960002899 hydroxyprogesterone Drugs 0.000 claims description 2
229960000908 idarubicin Drugs 0.000 claims description 2
229960001101 ifosfamide Drugs 0.000 claims description 2
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 2
229940047124 interferons Drugs 0.000 claims description 2
229960001614 levamisole Drugs 0.000 claims description 2
208000014018 liver neoplasm Diseases 0.000 claims description 2
229960002247 lomustine Drugs 0.000 claims description 2
229960004961 mechlorethamine Drugs 0.000 claims description 2
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 2
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims description 2
229960002985 medroxyprogesterone acetate Drugs 0.000 claims description 2
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 2
229960004296 megestrol acetate Drugs 0.000 claims description 2
229960001924 melphalan Drugs 0.000 claims description 2
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 2
229960001428 mercaptopurine Drugs 0.000 claims description 2
229960000485 methotrexate Drugs 0.000 claims description 2
229960004584 methylprednisolone Drugs 0.000 claims description 2
229960001566 methyltestosterone Drugs 0.000 claims description 2
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 2
229960004857 mitomycin Drugs 0.000 claims description 2
229960000350 mitotane Drugs 0.000 claims description 2
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
229960001156 mitoxantrone Drugs 0.000 claims description 2
208000025113 myeloid leukemia Diseases 0.000 claims description 2
239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
229960000952 pipobroman Drugs 0.000 claims description 2
NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 claims description 2
229960003171 plicamycin Drugs 0.000 claims description 2
229960005205 prednisolone Drugs 0.000 claims description 2
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 2
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
229960004618 prednisone Drugs 0.000 claims description 2
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 2
229960000624 procarbazine Drugs 0.000 claims description 2
108091006082 receptor inhibitors Proteins 0.000 claims description 2
229960001052 streptozocin Drugs 0.000 claims description 2
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 2
229960001603 tamoxifen Drugs 0.000 claims description 2
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 2
229960001278 teniposide Drugs 0.000 claims description 2
229960005353 testolactone Drugs 0.000 claims description 2
BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 claims description 2
229960003604 testosterone Drugs 0.000 claims description 2
229960003087 tioguanine Drugs 0.000 claims description 2
XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims description 2
229960005026 toremifene Drugs 0.000 claims description 2
229950001353 tretamine Drugs 0.000 claims description 2
IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 claims description 2
229960005294 triamcinolone Drugs 0.000 claims description 2
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 2
229960001055 uracil mustard Drugs 0.000 claims description 2
208000010570 urinary bladder carcinoma Diseases 0.000 claims description 2
229960003048 vinblastine Drugs 0.000 claims description 2
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
229960004528 vincristine Drugs 0.000 claims description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
229960004355 vindesine Drugs 0.000 claims description 2
UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 2
GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
229960002932 anastrozole Drugs 0.000 claims 1
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
229960004117 capecitabine Drugs 0.000 claims 1
CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 claims 1
230000003325 follicular Effects 0.000 claims 1
229960002913 goserelin Drugs 0.000 claims 1
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
229960003881 letrozole Drugs 0.000 claims 1
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
201000007270 liver cancer Diseases 0.000 claims 1
210000001685 thyroid gland Anatomy 0.000 claims 1
210000003954 umbilical cord Anatomy 0.000 claims 1
210000004027 cell Anatomy 0.000 description 97
230000000694 effects Effects 0.000 description 61
DHMTURDWPRKSOA-RUZDIDTESA-N lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 description 49
108090000623 proteins and genes Proteins 0.000 description 34
150000001875 compounds Chemical class 0.000 description 33
102000004169 proteins and genes Human genes 0.000 description 33
235000018102 proteins Nutrition 0.000 description 30
102000043136 MAP kinase family Human genes 0.000 description 26
108091054455 MAP kinase family Proteins 0.000 description 26
230000004913 activation Effects 0.000 description 23
238000000034 method Methods 0.000 description 23
239000003795 chemical substances by application Substances 0.000 description 22
102000005962 receptors Human genes 0.000 description 21
108020003175 receptors Proteins 0.000 description 21
230000005764 inhibitory process Effects 0.000 description 19
239000003814 drug Substances 0.000 description 15
230000000903 blocking effect Effects 0.000 description 13
230000026731 phosphorylation Effects 0.000 description 13
238000006366 phosphorylation reaction Methods 0.000 description 13
239000000203 mixture Substances 0.000 description 12
101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 11
102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 11
229940079593 drug Drugs 0.000 description 11
230000002401 inhibitory effect Effects 0.000 description 11
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 11
230000012010 growth Effects 0.000 description 10
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
239000000843 powder Substances 0.000 description 10
108010076667 Caspases Proteins 0.000 description 9
102000011727 Caspases Human genes 0.000 description 9
101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
238000003556 assay Methods 0.000 description 9
201000010099 disease Diseases 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
231100000673 dose–response relationship Toxicity 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
239000007787 solid Substances 0.000 description 9
108090000397 Caspase 3 Proteins 0.000 description 8
102000003952 Caspase 3 Human genes 0.000 description 8
108091000080 Phosphotransferase Proteins 0.000 description 8
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 8
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
230000000259 anti-tumor effect Effects 0.000 description 8
239000003446 ligand Substances 0.000 description 8
102000020233 phosphotransferase Human genes 0.000 description 8
239000000758 substrate Substances 0.000 description 8
102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 7
101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 7
230000001640 apoptogenic effect Effects 0.000 description 7
230000005735 apoptotic response Effects 0.000 description 7
230000030833 cell death Effects 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
238000000338 in vitro Methods 0.000 description 7
230000006698 induction Effects 0.000 description 7
230000011664 signaling Effects 0.000 description 7
239000000243 solution Substances 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 6
108040008097 MAP kinase activity proteins Proteins 0.000 description 6
102000019149 MAP kinase activity proteins Human genes 0.000 description 6
102000038030 PI3Ks Human genes 0.000 description 6
108091007960 PI3Ks Proteins 0.000 description 6
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 6
238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
231100000331 toxic Toxicity 0.000 description 6
230000002588 toxic effect Effects 0.000 description 6
108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 5
102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 5
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 5
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 5
238000013459 approach Methods 0.000 description 5
239000002775 capsule Substances 0.000 description 5
239000013611 chromosomal DNA Substances 0.000 description 5
239000012636 effector Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 5
235000019359 magnesium stearate Nutrition 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
239000000126 substance Substances 0.000 description 5
230000002459 sustained effect Effects 0.000 description 5
210000004881 tumor cell Anatomy 0.000 description 5
230000000381 tumorigenic effect Effects 0.000 description 5
238000000035 BCA protein assay Methods 0.000 description 4
102100029855 Caspase-3 Human genes 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
102100030708 GTPase KRas Human genes 0.000 description 4
101710113436 GTPase KRas Proteins 0.000 description 4
101000793880 Homo sapiens Caspase-3 Proteins 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
102000004357 Transferases Human genes 0.000 description 4
108090000992 Transferases Proteins 0.000 description 4
102000004142 Trypsin Human genes 0.000 description 4
108090000631 Trypsin Proteins 0.000 description 4
230000000692 anti-sense effect Effects 0.000 description 4
229940041181 antineoplastic drug Drugs 0.000 description 4
238000013461 design Methods 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
238000005259 measurement Methods 0.000 description 4
239000012528 membrane Substances 0.000 description 4
230000035772 mutation Effects 0.000 description 4
230000000861 pro-apoptotic effect Effects 0.000 description 4
239000000377 silicon dioxide Substances 0.000 description 4
235000012239 silicon dioxide Nutrition 0.000 description 4
239000006104 solid solution Substances 0.000 description 4
229940124597 therapeutic agent Drugs 0.000 description 4
239000012588 trypsin Substances 0.000 description 4
231100000588 tumorigenic Toxicity 0.000 description 4
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
238000001262 western blot Methods 0.000 description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
XYNHQVIVVBWVAG-UHFFFAOYSA-N 4h-cyclohepta[f]quinoline Chemical class C1=CC=CC=C2C3=CC=CNC3=CC=C21 XYNHQVIVVBWVAG-UHFFFAOYSA-N 0.000 description 3
201000009030 Carcinoma Diseases 0.000 description 3
102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 3
102000009024 Epidermal Growth Factor Human genes 0.000 description 3
101800003838 Epidermal growth factor Proteins 0.000 description 3
108010038807 Oligopeptides Proteins 0.000 description 3
102000015636 Oligopeptides Human genes 0.000 description 3
238000012288 TUNEL assay Methods 0.000 description 3
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
238000003782 apoptosis assay Methods 0.000 description 3
239000000872 buffer Substances 0.000 description 3
230000022131 cell cycle Effects 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
238000011284 combination treatment Methods 0.000 description 3
239000003599 detergent Substances 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
229940116977 epidermal growth factor Drugs 0.000 description 3
238000000684 flow cytometry Methods 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
238000002372 labelling Methods 0.000 description 3
230000005923 long-lasting effect Effects 0.000 description 3
239000006166 lysate Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
229930014626 natural product Natural products 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
238000001959 radiotherapy Methods 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000013519 translation Methods 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
201000005112 urinary bladder cancer Diseases 0.000 description 3
101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
208000001333 Colorectal Neoplasms Diseases 0.000 description 2
229920002785 Croscarmellose sodium Polymers 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
101150029707 ERBB2 gene Proteins 0.000 description 2
102100039788 GTPase NRas Human genes 0.000 description 2
102000018898 GTPase-Activating Proteins Human genes 0.000 description 2
108091006094 GTPase-accelerating proteins Proteins 0.000 description 2
101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 2
102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 2
108060006687 MAP kinase kinase kinase Proteins 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
239000002033 PVDF binder Substances 0.000 description 2
102000006382 Ribonucleases Human genes 0.000 description 2
108010083644 Ribonucleases Proteins 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
238000002441 X-ray diffraction Methods 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
229940100198 alkylating agent Drugs 0.000 description 2
239000002168 alkylating agent Substances 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
230000000340 anti-metabolite Effects 0.000 description 2
229940100197 antimetabolite Drugs 0.000 description 2
239000002256 antimetabolite Substances 0.000 description 2
238000003149 assay kit Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
239000003183 carcinogenic agent Substances 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
230000005754 cellular signaling Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
238000002591 computed tomography Methods 0.000 description 2
229960001681 croscarmellose sodium Drugs 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
239000006196 drop Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000000546 effect on cell death Effects 0.000 description 2
238000001378 electrochemiluminescence detection Methods 0.000 description 2
HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 2
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
238000005558 fluorometry Methods 0.000 description 2
239000007789 gas Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
101150098203 grb2 gene Proteins 0.000 description 2
238000000227 grinding Methods 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
230000006548 oncogenic transformation Effects 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
229920001993 poloxamer 188 Polymers 0.000 description 2
229920002981 polyvinylidene fluoride Polymers 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
230000001323 posttranslational effect Effects 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000005522 programmed cell death Effects 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000004952 protein activity Effects 0.000 description 2
238000011002 quantification Methods 0.000 description 2
238000012552 review Methods 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000007921 spray Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000829 suppository Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
GZDRODOYEFEHGG-NUDCOPPTSA-N (4s)-4-[[(2s)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2s)-1-[[(2s)-3-carboxy-1-oxo-1-[[2-oxo-4-(trifluoromethyl)chromen-7-yl]amino]propan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound FC(F)(F)C1=CC(=O)OC2=CC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(C)=O)C(C)C)=CC=C21 GZDRODOYEFEHGG-NUDCOPPTSA-N 0.000 description 1
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
108020004491 Antisense DNA Proteins 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
244000056139 Brassica cretica Species 0.000 description 1
235000003351 Brassica cretica Nutrition 0.000 description 1
235000003343 Brassica rupestris Nutrition 0.000 description 1
206010048832 Colon adenoma Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
102100030011 Endoribonuclease Human genes 0.000 description 1
101710199605 Endoribonuclease Proteins 0.000 description 1
206010016935 Follicular thyroid cancer Diseases 0.000 description 1
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
230000004668 G2/M phase Effects 0.000 description 1
102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
102100029974 GTPase HRas Human genes 0.000 description 1
108091006109 GTPases Proteins 0.000 description 1
108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 1
102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 1
241001326189 Gyrodactylus prostae Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
101001130437 Homo sapiens Ras-related protein Rap-2b Proteins 0.000 description 1
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
206010064912 Malignant transformation Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
108010055723 PDGF receptor tyrosine kinase Proteins 0.000 description 1
239000012828 PI3K inhibitor Substances 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
108010064785 Phospholipases Proteins 0.000 description 1
102000015439 Phospholipases Human genes 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
102000003923 Protein Kinase C Human genes 0.000 description 1
108090000315 Protein Kinase C Proteins 0.000 description 1
102100031421 Ras-related protein Rap-2b Human genes 0.000 description 1
102000042463 Rho family Human genes 0.000 description 1
108091078243 Rho family Proteins 0.000 description 1
102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 1
230000018199 S phase Effects 0.000 description 1
102000014400 SH2 domains Human genes 0.000 description 1
108050003452 SH2 domains Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
101800004564 Transforming growth factor alpha Proteins 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000009692 acute damage Effects 0.000 description 1
239000002487 adenosine deaminase inhibitor Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
150000008052 alkyl sulfonates Chemical class 0.000 description 1
230000008841 allosteric interaction Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
238000002841 anti-cancer assay Methods 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
239000003816 antisense DNA Substances 0.000 description 1
229960004754 astemizole Drugs 0.000 description 1
GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
230000035578 autophosphorylation Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000003560 cancer drug Substances 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
229960002559 chlorotrianisene Drugs 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
201000010897 colon adenocarcinoma Diseases 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
238000003271 compound fluorescence assay Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000006126 farnesylation Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000007421 fluorometric assay Methods 0.000 description 1
239000004052 folic acid antagonist Substances 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229940022353 herceptin Drugs 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
125000001183 hydrocarbyl group Chemical group 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000005917 in vivo anti-tumor Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006882 induction of apoptosis Effects 0.000 description 1
239000003999 initiator Substances 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
229910021432 inorganic complex Inorganic materials 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
230000004068 intracellular signaling Effects 0.000 description 1
OMEUGRCNAZNQLN-UHFFFAOYSA-N isis 5132 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(S)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)C(O)C1 OMEUGRCNAZNQLN-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
125000003473 lipid group Chemical group 0.000 description 1
229960003088 loratadine Drugs 0.000 description 1
JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
239000006210 lotion Substances 0.000 description 1
201000005249 lung adenocarcinoma Diseases 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
230000036212 malign transformation Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001055 monoterpenyl- group Chemical group 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
235000010460 mustard Nutrition 0.000 description 1
230000000869 mutational effect Effects 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
238000009521 phase II clinical trial Methods 0.000 description 1
238000009522 phase III clinical trial Methods 0.000 description 1
229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
108091005981 phosphorylated proteins Proteins 0.000 description 1
DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
238000012342 propidium iodide staining Methods 0.000 description 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
239000003909 protein kinase inhibitor Substances 0.000 description 1
230000009822 protein phosphorylation Effects 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
230000005855 radiation Effects 0.000 description 1
108700042226 ras Genes Proteins 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
102200006531 rs121913529 Human genes 0.000 description 1
150000003335 secondary amines Chemical group 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000008054 signal transmission Effects 0.000 description 1
102000030938 small GTPase Human genes 0.000 description 1
108060007624 small GTPase Proteins 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000008685 targeting Effects 0.000 description 1
229960000351 terfenadine Drugs 0.000 description 1
208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000011199 transformed cell apoptotic process Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
229960000575 trastuzumab Drugs 0.000 description 1
150000004654 triazenes Chemical class 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000012800 visualization Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000036642 wellbeing Effects 0.000 description 1
229940033942 zoladex Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NO20014897A 1999-04-09 2001-10-08 Anvendelse av en FPT-inhibitor ved fremstilling av et farmasoytisk preparat for behandling av kreft i en pasient og for regresjon av tumorvolum i en kreftpasient NO329133B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/289,255 US6316462B1 (en)	1999-04-09	1999-04-09	Methods of inducing cancer cell death and tumor regression
PCT/US2000/009124 WO2000061145A1 (en)	1999-04-09	2000-04-06	Methods of inducing cancer cell death and tumor regression

Publications (3)

Publication Number	Publication Date
NO20014897D0 NO20014897D0 (no)	2001-10-08
NO20014897L NO20014897L (no)	2001-12-10
NO329133B1 true NO329133B1 (no)	2010-08-30

Family

ID=23110723

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20014897A NO329133B1 (no)	1999-04-09	2001-10-08	Anvendelse av en FPT-inhibitor ved fremstilling av et farmasoytisk preparat for behandling av kreft i en pasient og for regresjon av tumorvolum i en kreftpasient

Country Status (24)

Country	Link
US (1)	US6316462B1 (de)
EP (1)	EP1165078B1 (de)
JP (1)	JP2003529540A (de)
CN (1)	CN100421661C (de)
AR (1)	AR023400A1 (de)
AT (1)	ATE347360T1 (de)
AU (1)	AU783177B2 (de)
BR (1)	BR0009670A (de)
CA (1)	CA2364675A1 (de)
CY (1)	CY1107545T1 (de)
DE (1)	DE60032226T2 (de)
DK (1)	DK1165078T3 (de)
ES (1)	ES2275505T3 (de)
HK (1)	HK1038512B (de)
HU (1)	HUP0200773A3 (de)
MX (1)	MXPA01010211A (de)
MY (1)	MY120841A (de)
NO (1)	NO329133B1 (de)
NZ (1)	NZ514628A (de)
PE (1)	PE20010025A1 (de)
PT (1)	PT1165078E (de)
TW (1)	TWI255184B (de)
WO (1)	WO2000061145A1 (de)
ZA (1)	ZA200108258B (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6524832B1 (en)	1994-02-04	2003-02-25	Arch Development Corporation	DNA damaging agents in combination with tyrosine kinase inhibitors
US20030060434A1 (en) *	1997-02-18	2003-03-27	Loretta Nielsen	Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030064949A1 (en) *	1998-02-17	2003-04-03	Loretta Nielsen	Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
ZA9811162B (en)	1997-12-12	2000-06-07	Genentech Inc	Treatment with anti-ERBB2 antibodies.
EP2298311B1 (de)	1999-01-13	2012-05-09	Bayer HealthCare LLC	Omega-carboxyarylsubstituierte-Diphenyl-Harnstoffe als p38-Kinasehemmer
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20030086924A1 (en) *	1999-06-25	2003-05-08	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
US6949245B1 (en) *	1999-06-25	2005-09-27	Genentech, Inc.	Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en) *	1999-06-25	2004-01-22	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
AR024464A1 (es) *	1999-06-25	2002-10-02	Genentech Inc	Anticuerpos anti-erbb2 humanizados.
US7041292B1 (en)	1999-06-25	2006-05-09	Genentech, Inc.	Treating prostate cancer with anti-ErbB2 antibodies
AU2001246477A1 (en) *	2000-02-29	2001-09-12	Janssen Pharmaceutica N.V.	Farnesyl protein transferase inhibitor combinations with platinum compounds
DE10017480A1 (de) *	2000-04-07	2001-10-11	Transmit Technologietransfer	Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
EP1280923A2 (de) *	2000-04-28	2003-02-05	Millennium Pharmaceuticals, Inc.	14094, ein angehörige der menschlichen trypsin-familie, und dessen verwendungen
WO2001089566A1 (en)	2000-05-19	2001-11-29	Genentech, Inc.	Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
MXPA03003011A (es) *	2000-10-05	2003-07-14	George Q Daley	Metodos para inducir muerte de celulas cancerosas y regresion de tumores.
US20020077301A1 (en) *	2000-10-05	2002-06-20	Whitehead Institute For Biomedical Research	Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
US7141576B2 (en)	2001-01-16	2006-11-28	Smithkline Beecham (Cork) Limited	Cancer treatment method
WO2002057269A1 (en)	2001-01-18	2002-07-25	Schering Corporation	Synthesis of temozolomide and analogs
NZ516873A (en) *	2001-02-12	2003-11-28	Warner Lambert Co	Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
US6703400B2 (en)	2001-02-23	2004-03-09	Schering Corporation	Methods for treating multidrug resistance
WO2003047697A2 (en) *	2001-11-30	2003-06-12	Schering Corporation	Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
EP1453513A1 (de) *	2001-12-03	2004-09-08	Schering Corporation	Verwendung von fpt inhibitoren und mindestens zwei anderen ant-krebsmitteln zur krebsbehandlung
DK1478358T3 (da)	2002-02-11	2013-10-07	Bayer Healthcare Llc	Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
AU2003231098A1 (en)	2002-04-25	2003-11-10	University Of Connecticut Health Center	Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US6984389B2 (en) *	2002-04-25	2006-01-10	University Of Connecticut Health Center	Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
MXPA04011624A (es) *	2002-05-24	2005-03-07	Schering Corp	Anticuerpo neutralizante humano anti-igfr.
US20060270643A1 (en) *	2002-10-31	2006-11-30	Chawnshang Chang	Hyfroxyflutamide induced pathways related to androgen receptor negative prostate cancer cells
US20050101576A1 (en) *	2003-11-06	2005-05-12	Novacea, Inc.	Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
UY28213A1 (es)	2003-02-28	2004-09-30	Bayer Pharmaceuticals Corp	Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
US8168568B1 (en)	2003-03-10	2012-05-01	The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Combinatorial therapy for protein signaling diseases
EP2365001A3 (de) *	2003-05-01	2012-03-28	Imclone LLC	Vollständig humane Antikörper, die sich gegen den Wachstumfaktor-1-Rezeptor richten, der dem menschlichen Insulin ähnelt
EP1636585B2 (de)	2003-05-20	2012-06-13	Bayer HealthCare LLC	Diaryl-harnstoffe mit kinasehemmender wirkung
PL1663978T3 (pl)	2003-07-23	2008-04-30	Bayer Healthcare Llc	Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
EP1694850B1 (de)	2003-11-12	2011-06-29	Schering Corporation	Plasmidsystem zur expression mehrerer gene
JP4691041B2 (ja)	2003-11-20	2011-06-01	チルドレンズホスピタルメディカルセンター	Ｇｔｐアーゼ阻害剤および使用方法
AR046639A1 (es) *	2003-11-21	2005-12-14	Schering Corp	Combinaciones terapeuticas de anticuerpo anti- igfr1
US20050171182A1 (en) *	2003-12-11	2005-08-04	Roger Briesewitz	Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
AU2005209909B8 (en) *	2004-02-03	2009-01-15	The Regents Of The University Of Michigan	Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
US20060205810A1 (en) *	2004-11-24	2006-09-14	Schering Corporation	Platinum therapeutic combinations
EP2281841A3 (de) *	2004-12-03	2013-10-23	Merck Sharp & Dohme Corp.	Biomarker zur Vorauswahl von Patienten für eine Anti-IGF1R Therapie
EP3698807A1 (de)	2005-01-21	2020-08-26	Genentech, Inc.	Fixe dosierung von her-antikörpern
RS53128B (sr)	2005-02-23	2014-06-30	Genentech Inc.	Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba
US7524831B2 (en) *	2005-03-02	2009-04-28	Schering Corporation	Treatments for Flaviviridae virus infection
CN101222926B (zh) *	2005-04-15	2013-07-17	默沙东公司	用于治疗或预防癌症的方法和组合物
EP3530736A3 (de) *	2005-05-09	2019-11-06	ONO Pharmaceutical Co., Ltd.	Humane monoklonale antikörper für den programmierten tod 1 (pd-1) und verfahren zur behandlung von krebs mit pd-1-antikörpern allein oder in kombination mit anderen immunotherapeutika
BRPI0611800A2 (pt) *	2005-06-15	2008-12-09	Schering Corp	formulaÇço estÁvel de anticorpo
CA2678008C (en)	2005-06-17	2013-07-30	Imclone Systems Incorporated	Methods of treating a secondary bone tumor with anti-pdgfralpha antibodies
US8101799B2 (en) *	2005-07-21	2012-01-24	Ardea Biosciences	Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US9095581B2 (en)	2005-07-21	2015-08-04	Ardea Biosciences, Inc.	Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof
WO2007016539A2 (en)	2005-07-29	2007-02-08	Children's Hospital Medical Center	Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase
AU2007212447B2 (en) *	2006-02-03	2013-02-21	Imclone Llc	IGF-IR antagonists as adjuvants for treatment of prostate cancer
US7671067B2 (en) *	2006-02-09	2010-03-02	Enzon Pharmaceuticals, Inc.	Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
US7462627B2 (en) *	2006-02-09	2008-12-09	Enzon Pharmaceuticals, Inc.	Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
WO2008005469A2 (en) *	2006-06-30	2008-01-10	Schering Corporation	Igfbp2 biomarker
MX2009004555A (es) *	2006-10-25	2009-05-11	Schering Corp	Metodos de tratamiento de cancer de ovario.
MX2009008981A (es)	2007-03-02	2009-09-02	Genentech Inc	Prediccion de respuesta a un inhibidor her.
CA2686848A1 (en)	2007-05-08	2008-11-20	Schering Corporation	Methods of treatment using intravenous formulations comprising temozolomide
WO2008154249A2 (en)	2007-06-08	2008-12-18	Genentech, Inc.	Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en)	2007-06-08	2017-01-24	Genentech, Inc.	Gene expression markers of tumor resistance to HER2 inhibitor treatment
CA2694646C (en) *	2007-07-30	2017-09-05	Ardea Biosciences, Inc.	Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
US20110129549A1 (en) *	2008-04-17	2011-06-02	Liu Julie F	Tricyclic benzo[5,6]cyclohepta[1,2-b]pyridine derivatives and uses thereof
BRPI0812682A2 (pt)	2008-06-16	2010-06-22	Genentech Inc	tratamento de cáncer de mama metastático
TW201010732A (en) *	2008-08-29	2010-03-16	Enzon Pharmaceuticals Inc	Method of treating RAS associated cancer
US20100098654A1 (en) *	2008-10-21	2010-04-22	Fabio Pastorino	Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
KR20150036824A (ko)	2009-03-20	2015-04-07	제넨테크, 인크.	이중특이적 항-ｈｅｒ 항체
US20120121586A1 (en)	2009-05-29	2012-05-17	Astrid Kiermaier	Modulators for her2 signaling in her2 expressing patients with gastric cancer
ES2519348T3 (es)	2010-02-18	2014-11-06	Genentech, Inc.	Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer
WO2011146568A1 (en)	2010-05-19	2011-11-24	Genentech, Inc.	Predicting response to a her inhibitor
WO2012069466A1 (en)	2010-11-24	2012-05-31	Novartis Ag	Multispecific molecules
EP2655413B1 (de)	2010-12-23	2019-01-16	F.Hoffmann-La Roche Ag	Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
BR112014003431A2 (pt)	2011-08-17	2017-06-13	Genentech Inc	anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
WO2013063229A1 (en)	2011-10-25	2013-05-02	The Regents Of The University Of Michigan	Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
AU2012346540C1 (en)	2011-11-30	2019-07-04	Genentech, Inc.	ErbB3 mutations in cancer
WO2013083810A1 (en)	2011-12-09	2013-06-13	F. Hoffmann-La Roche Ag	Identification of non-responders to her2 inhibitors
WO2013148315A1 (en)	2012-03-27	2013-10-03	Genentech, Inc.	Diagnosis and treatments relating to her3 inhibitors
US9980942B2 (en)	2012-05-02	2018-05-29	Children's Hospital Medical Center	Rejuvenation of precursor cells
RU2692773C2 (ru)	2012-11-30	2019-06-27	Ф.Хоффманн-Ля Рош Аг	Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1
CA2946759A1 (en) *	2014-04-25	2015-10-29	Memorial Sloan-Kettering Cancer Center	Treatment of h-ras-driven tumors
US10028503B2 (en)	2014-06-18	2018-07-24	Children's Hospital Medical Center	Platelet storage methods and compositions for same
US20190151346A1 (en)	2016-05-10	2019-05-23	INSERM (Institute National de la Santé et de la Recherche Médicale)	Combinations therapies for the treatment of cancer
CN114450027A (zh)	2019-08-16	2022-05-06	儿童医院医疗中心	用cdc42特异性抑制剂治疗受试者的方法
EP4426303B1 (de)	2021-11-02	2025-10-08	Semmelweis Egyetem	Farnesyl-transferase inhibitoren und kras inhibitoren zur behandlung von kras mutant krebs
CN120053663B (zh) *	2024-04-15	2025-12-12	天津医科大学	Sp/klf转录因子抑制剂与去乙酰化酶抑制剂组合的制药用途

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2546577B2 (de)	1975-10-17	1981-04-02	Sandoz-Patent-GmbH, 7850 Lörrach	Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden
EP0214092A1 (de)	1985-08-08	1987-03-11	Ciba-Geigy Ag	Absorption von psychoaktiven 2-Aryl-pyrazoloquinolinen in Form einer festen Molekulardispersion in Polyvinylpyrrolidon
US4764378A (en)	1986-02-10	1988-08-16	Zetachron, Inc.	Buccal drug dosage form
US5089496A (en)	1986-10-31	1992-02-18	Schering Corporation	Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US4826853A (en)	1986-10-31	1989-05-02	Schering Corporation	6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
WO1989006692A1 (en)	1988-01-12	1989-07-27	Genentech, Inc.	Method of treating tumor cells by inhibiting growth factor receptor function
JPH0678315B2 (ja)	1988-04-28	1994-10-05	シェリング・コーポレーション	新規なベンゾピリド‐ピペリジン、ピペリジリデンおよびピペラジン化合物、組成物、製造法および利用法
US5393890A (en)	1988-06-02	1995-02-28	Ajinomoto Co., Inc.	Piperidine derivatives and hypotensives containing the same
DE3830353A1 (de)	1988-09-07	1990-03-15	Basf Ag	Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
DE69120430D1 (de)	1990-12-18	1996-07-25	Wellcome Found	Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
ATE153336T1 (de)	1992-03-27	1997-06-15	Schering Corp	Verbrückte bis-aryl-carbinol-derivate, zusammensetzungen und ihre verwendung
US5512293A (en)	1992-07-23	1996-04-30	Alza Corporation	Oral sustained release drug delivery device
FR2698560B1 (fr)	1992-11-30	1995-02-03	Virbac Laboratoires	Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
IL111235A (en)	1993-10-15	2001-03-19	Schering Plough Corp	Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
JP2875393B2 (ja)	1993-10-15	1999-03-31	シェーリングコーポレイション	Ｇ−タンパク質機能の阻害および増殖性疾患の治療に有用な三環式カルバメート化合物
US5721236A (en)	1993-10-15	1998-02-24	Schering Corporation	Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5719148A (en)	1993-10-15	1998-02-17	Schering Corporation	Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5661152A (en)	1993-10-15	1997-08-26	Schering Corporation	Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5464840A (en)	1993-12-06	1995-11-07	Schering Corporation	Tricyclic derivatives, compositions and methods of use
US5523095A (en)	1993-12-15	1996-06-04	Eastman Chemical Company	Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends
TW406022B (en)	1994-12-19	2000-09-21	Daiichi Seiyaku Co	Method for producing slow-release granular agents
US5684013A (en)	1995-03-24	1997-11-04	Schering Corporation	Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5700806A (en)	1995-03-24	1997-12-23	Schering Corporation	Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117798A (en)	1995-04-07	2001-11-25	Schering Plough Corp	Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
US5712280A (en)	1995-04-07	1998-01-27	Schering Corporation	Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
DE69635114T2 (de)	1995-08-09	2006-03-02	Banyu Pharmaceutical Co., Ltd.	Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids
US5874442A (en)	1995-12-22	1999-02-23	Schering-Plough Corporation	Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
SK86198A3 (en) *	1995-12-22	1999-02-11	Schering Corp	Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
JP2000504023A (ja)	1996-04-03	2000-04-04	メルクエンドカンパニーインコーポレーテッド	癌治療方法
EP0910385A4 (de)	1996-04-15	1999-12-22	Univ Pennsylvania	Sensibilisierung von zellen zur strahlen- und chemotherapie
WO1997038664A2 (en)	1996-04-18	1997-10-23	Merck & Co., Inc.	A method of treating cancer
AU3215197A (en)	1996-05-30	1998-01-05	Merck & Co., Inc.	A method of treating cancer
DE69730241T2 (de)	1996-06-28	2005-08-11	Schering Corp.	Feste lösung eines fungizids mit erhöhter bioverfügbarkeit
US5972381A (en)	1996-06-28	1999-10-26	Schering Corporation	Solid solution of an antifungal agent with enhanced bioavailability
US5958890A (en)	1996-09-13	1999-09-28	Schering Corporation	Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5861395A (en)	1996-09-13	1999-01-19	Schering Corporation	Compounds useful for inhibition of farnesyl proteins transferase
US6040305A (en)	1996-09-13	2000-03-21	Schering Corporation	Compounds useful for inhibition of farnesyl protein transferase
US5985879A (en)	1996-09-13	1999-11-16	Schering Corporation	Compounds useful for inhibition of farnesyl protein transferase
US5945429A (en)	1996-09-13	1999-08-31	Schering Corporation	Compounds useful for inhibition of farnesyl protein transferase
US6071907A (en)	1996-09-13	2000-06-06	Schering Corporation	Tricyclic compounds useful as FPT inhibitors
TR199901275T2 (xx)	1996-09-13	1999-09-21	Schering Corporation	Farnezil protein transferaz inhibisyonu i�in yararl� bile�ikler.
US5965570A (en)	1996-09-13	1999-10-12	Schering Corporation	Tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase
US6030982A (en)	1996-09-13	2000-02-29	Schering Corporationm	Compounds useful for inhibition of farnesyl protein transferase
DE69837754T2 (de)	1997-02-18	2008-02-07	Canji, Inc., San Diego	Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung
GB9801231D0 (en)	1997-06-05	1998-03-18	Merck & Co Inc	A method of treating cancer
US5925639A (en)	1997-06-17	1999-07-20	Schering Corporation	Keto amide derivatives useful as farnesyl protein transferase inhibitors
US5852034A (en)	1997-06-17	1998-12-22	Schering Corporation	Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors
US5877177A (en)	1997-06-17	1999-03-02	Schering Corporation	Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5939416A (en)	1997-06-17	1999-08-17	Schering Corporation	Benzo (5,6) cycloheptapyridine compounds useful as farnesyl protein transferase inhibitors
US5958940A (en)	1997-09-11	1999-09-28	Schering Corporation	Tricyclic compounds useful as inhibitors of farnesyl-protein transferase
ZA9811162B (en)	1997-12-12	2000-06-07	Genentech Inc	Treatment with anti-ERBB2 antibodies.
NZ504834A (en)	1997-12-22	2001-12-21	Schering Corp	Tricyclic amide molecular dispersion composition with enhanced bioavailability

1999
- 1999-04-09 US US09/289,255 patent/US6316462B1/en not_active Expired - Fee Related
2000
- 2000-04-06 ES ES00921765T patent/ES2275505T3/es not_active Expired - Lifetime
- 2000-04-06 EP EP00921765A patent/EP1165078B1/de not_active Expired - Lifetime
- 2000-04-06 HK HK02100132.7A patent/HK1038512B/en not_active IP Right Cessation
- 2000-04-06 AU AU42041/00A patent/AU783177B2/en not_active Ceased
- 2000-04-06 MX MXPA01010211A patent/MXPA01010211A/es active IP Right Grant
- 2000-04-06 NZ NZ514628A patent/NZ514628A/xx not_active IP Right Cessation
- 2000-04-06 JP JP2000610478A patent/JP2003529540A/ja active Pending
- 2000-04-06 DE DE60032226T patent/DE60032226T2/de not_active Expired - Lifetime
- 2000-04-06 DK DK00921765T patent/DK1165078T3/da active
- 2000-04-06 PT PT00921765T patent/PT1165078E/pt unknown
- 2000-04-06 HU HU0200773A patent/HUP0200773A3/hu unknown
- 2000-04-06 TW TW089106323A patent/TWI255184B/zh not_active IP Right Cessation
- 2000-04-06 CA CA002364675A patent/CA2364675A1/en not_active Abandoned
- 2000-04-06 AR ARP000101576A patent/AR023400A1/es unknown
- 2000-04-06 BR BR0009670-9A patent/BR0009670A/pt not_active IP Right Cessation
- 2000-04-06 CN CNB008085293A patent/CN100421661C/zh not_active Expired - Fee Related
- 2000-04-06 WO PCT/US2000/009124 patent/WO2000061145A1/en not_active Ceased
- 2000-04-06 AT AT00921765T patent/ATE347360T1/de not_active IP Right Cessation
- 2000-04-07 MY MYPI20001455A patent/MY120841A/en unknown
- 2000-04-07 PE PE2000000317A patent/PE20010025A1/es not_active Application Discontinuation
2001
- 2001-10-08 ZA ZA200108258A patent/ZA200108258B/xx unknown
- 2001-10-08 NO NO20014897A patent/NO329133B1/no not_active IP Right Cessation
2007
- 2007-03-01 CY CY20071100296T patent/CY1107545T1/el unknown

Also Published As

Publication number	Publication date
NO20014897D0 (no)	2001-10-08
US6316462B1 (en)	2001-11-13
MY120841A (en)	2005-11-30
NO20014897L (no)	2001-12-10
AU4204100A (en)	2000-11-14
HUP0200773A3 (en)	2003-04-28
NZ514628A (en)	2004-01-30
DE60032226T2 (de)	2007-10-11
CA2364675A1 (en)	2000-10-19
CN100421661C (zh)	2008-10-01
CY1107545T1 (el)	2013-03-13
ZA200108258B (en)	2003-03-26
JP2003529540A (ja)	2003-10-07
AR023400A1 (es)	2002-09-04
CN1364084A (zh)	2002-08-14
TWI255184B (en)	2006-05-21
PT1165078E (pt)	2007-02-28
EP1165078B1 (de)	2006-12-06
HK1038512A1 (en)	2002-03-22
HUP0200773A2 (hu)	2002-07-29
PE20010025A1 (es)	2001-02-05
HK1038512B (en)	2007-04-27
ES2275505T3 (es)	2007-06-16
WO2000061145A1 (en)	2000-10-19
BR0009670A (pt)	2002-01-15
AU783177B2 (en)	2005-09-29
EP1165078A1 (de)	2002-01-02
ATE347360T1 (de)	2006-12-15
DE60032226D1 (de)	2007-01-18
MXPA01010211A (es)	2002-09-18
DK1165078T3 (da)	2007-04-16

Legal Events

Date	Code	Title	Description
2011-11-28	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US6316462B1 (en)	2001-11-13	Methods of inducing cancer cell death and tumor regression
US8629135B2 (en)	2014-01-14	Pharmaceutical compositions comprising RET inhibitors and methods for the treatment of cancer
JP6575952B2 (ja)	2019-09-18	イブルチニブ併用療法
JP5110756B2 (ja)	2012-12-26	癌を処置するための相乗方法および組成物
US6777415B2 (en)	2004-08-17	Methods of inducing cancer cell death and tumor regression
EP2968379B1 (de)	2021-05-05	Prodrugs von etoposid zur verwendung beim targeting von krebsstammzellen
WO2006002119A2 (en)	2006-01-05	Kinase inhibitors for treating cancers
AU2002211862A1 (en)	2002-06-27	Methods of inducing cancer cell death and tumor regression
WO2023104151A1 (zh)	2023-06-15	治疗肿瘤的药物组合及用途
SK285584B6 (sk)	2007-04-05	Použitie 11-(4-piperidylidén)-5H-benzo[5,6]-cyklohepta[1,2- b]pyridínovej zlúčeniny ako inhibítora farnezyl-proteíntransferázy na výrobu liečiva na liečenie proliferačného ochorenia
EP4588485A1 (de)	2025-07-23	Pharmazeutische kombination aus fak-inhibitor und topoisomerase-inhibitor und verwendung davon
JP2025528528A (ja)	2025-08-28	Ｆａｋ阻害剤及びｅｇｆｒ－ｔｋｉの薬学的組合せ及び使用
KR20250052367A (ko)	2025-04-18	Fak 억제제와 미세소관 억제제의 약제학적 병용물 및 이의 용도
KR101318806B1 (ko)	2013-10-16	메틸페니데이트 유도체 및 그 용도
US20230094843A1 (en)	2023-03-30	Pharmaceutical combination for treating tumors and application thereof
AU2005248948A1 (en)	2006-02-02	Methods of inducing cancer cell death and tumor regression
HK40029376B (en)	2023-05-05	Drug therapy to inhibit chemotherapy-induced adverse effects and screening techniques and kits
Tseng	2005	PDK-1/AKT pathway as targets for chemosensitizing effects
HK1220365B (en)	2022-01-14	Etoposide prodrugs for use in targeting cancer stem cells